Issue title: Selected papers from the 6th China–France International Symposium “Stem Cells and Regenerative Medicine” and the first meeting of the France–China International CNRS Network (GDRI) CeSMeR, Nancy, 10–13 July 2016
Guest editors: J.-F. Stoltz, J. Magdalou and D. Bensoussan
Affiliations: Laboratoire français du Fractionnement et des Biotechnologies, les Ulis, France
Correspondence:
[*]
Corresponding author: Mazen Elzaabi, LFB, 3 avenue des Tropiques, 98958 les Ulis, France. E-mail: elzaabi@lfb.fr; Tel.: +33 1 69 82 10 59.
Abstract: CELLforCURE is a French Contract Development and Manufacturing Organization (CDMO) dedicated to industrialization and process development for routine manufacturing, GMP manufacturing for clinical and commercial batches and regulatory services and associated logistics. CELLforCURE is a subsidiary of LFB Group. Stem cells fields of application gather cell and gene therapy as well as tissue engineering. According to VisionGain survey, cell therapy medicinal products will remain predominant in the future. Clinical trials are sponsored either by universities or private companies. Most of clinical trials are performed in oncology (53%). More than 100 clinical trials are currently performed in France, involving 36 products in clinical phases II or II/III. Tomorrow’s regenerative medicine will be organ reconstruction using scaffolds and bioprinting technologies. The expected applications in the near future could be skin, cornea, blood vessels, retina, urethra and trachea. There are still important issues to overcome: create the vasculature and neuron connection. Solutions are expected regarding I) fundamental biology, in particular better understanding of IPS behavior and metabolism, precursor differentiation conditions, sustainability of induced genetic changes, II) technical approaches which involves injectable preservation medium, high density cells and centrifugation system.
Keywords: LFB, CELLforCURE, gene therapy, cell therapy, Contract Development and Manufacturing Organization
